Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 11/20 | 0.63 |
| ▸ | PHLPP2 | Q6ZVD8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.38 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | CD40 | P25942 | 1/20 | 0.34 |
| ▸ | CD40LG | P29965 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13182922 | 0.90 | ENPP2 (0.76) | ENPP2PHLPP2ALDH1A1HIF1APTPN1 | |
| SCHEMBL14001679 | 0.90 | ENPP2 (0.60) | ENPP2PHLPP2ALDH1A1HIF1APTPN1 | |
| SCHEMBL29927435 | 0.89 | ENPP2 (0.78) | ENPP2PHLPP2ALDH1A1HIF1APTPN1 | |
| SCHEMBL14001678 | 0.88 | ENPP2 (0.53) | ENPP2PHLPP2ALDH1A1HIF1APRMT1 | |
| SCHEMBL14523615 | 0.87 | ENPP2 (0.58) | ENPP2PHLPP2ALDH1A1PTPN1PRMT1 | |
| SCHEMBL14001682 | 0.86 | ENPP2 (0.53) | ENPP2PHLPP2ALDH1A1PTPN1PRMT1 | |
| SCHEMBL13088672 | 0.86 | ENPP2 (0.55) | ENPP2PHLPP2ALDH1A1HIF1APTPN1 | |
| SCHEMBL13088668 | 0.86 | ENPP2 (0.55) | ENPP2PHLPP2ALDH1A1HIF1APTPN1 | |
| SCHEMBL11911523 | 0.85 | ENPP2 (0.55) | ENPP2PHLPP2ALDH1A1HIF1APRMT1 | |
| SCHEMBL13088703 | 0.85 | ENPP2 (0.53) | ENPP2PHLPP2ALDH1A1PTPN1PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553359-B2 | Stable liquid formulations of anionic dyes | CLARIANT FINANCE (BVI) LIMITED (VG) | 2009-06-30 | — | — | US | disclosed |
| US-20080194815-A1 | Stable Liquid Formulations of Anionic Dyes | CLARIANT INTERNATIONAL LTD. (CH) | 2008-08-14 | — | — | US | disclosed |
| US-20070083040-A1 | Storagestable concentrated aqueous solutions of anionic dis-or tetrazo dyestuffs | CLARIANT FINANCE (BVI) LIMITED (VG) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194815-A1 | Stable Liquid Formulations of Anionic Dyes | ADH1A, ADH5, ADH1C | ENPP2 4505/4885PHLPP2 1737/4885ALDH1A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.